The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Anifrolumab Promising for Sustained Low Disease Activity in Patients with Lupus

Anifrolumab Promising for Sustained Low Disease Activity in Patients with Lupus

May 5, 2022 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR CONVERGENCE 2021—Using pooled data from the TULIP-1 and TULIP-2 clinical trials, researchers set out to identify whether more patients with systemic lupus erythematosus (SLE) being treated with anifrolumab achieved a low disease activity state than patients with SLE who received placebo.1-3 An analysis of the data was presented at ACR Convergence 2021 by Eric Morand, MD, head of the School of Clinical Sciences, Monash University, and director of Rheumatology, Monash Health, Melbourne, Australia.

You Might Also Like
  • Anifrolumab Promising for SLE
  • Study Says Low Disease-Activity State Can Reduce Lupus Organ Damage
  • Tocilizumab Monotherapy May Sustain Low Disease Activity in RA Patients
Explore This Issue
June 2022
Also By This Author
  • Supplemental Application for Denosumab Goes to FDA

Anifrolumab is a type I interferon receptor antagonist.3 On July 30, 2021, the U.S. Food & Drug Administration (FDA) approved anifrolumab for the treatment of adults with moderate to severe SLE who were also receiving standard therapy.4,5 (Note: See below for how this was defined.) The FDA approval was based on both TULIP trials.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The phase 3 TULIP-1 (NCT02446912) and TULIP-2 (NCT02446899) studies were randomized, placebo-controlled, 52-week trials during which 300 mg of intravenous anifrolumab was given every four weeks for 48 weeks to eligible patients with moderate to severe SLE despite standard therapy (i.e., treatment with at least one of the following agents or classes: oral glucocorticoids; antimalarials; and/or immunosuppressive agents, such as methotrexate, azathioprine and/or mycophenolate mofetil).

The study included patients classified as having SLE according to the ACR’s 1997 criteria. All patients were at least 18 years old and had moderate to severe disease, with an SLE Disease Activity Index 2000 (SLEDAI-2K) score of at least 6 points, organ-level involvement based on the British Isles Lupus Assessment Group (BILAG) assessment and a Physician’s Global Assessment (PGA) score of at least 1. During the studies, patients continued their existing SLE therapy at stable doses, except for patients receiving oral glucocorticoids, which were tapered.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The BILAG index is a standardized SLE disease activity assessment. Efficacy in the TULIP trials was demonstrated using the BILAG-based Combined Lupus Assessment (BICLA) response, which includes reducing all severe or moderately severe disease activity, no worsening in other organ systems, no worsening in disease activity, no discontinuation of the trial intervention and no use of restricted medications beyond those allowed in the protocol.

Pooled data for the 300 mg of anifrolumab (n=360) and placebo (n=366) groups were analyzed by time point for achieving a lupus low disease activity state (LLDAS), defined as:

  • An SLEDAI-2K score of 4 or less without major organ activity;
  • No new disease activity;
  • A PGA score (0–3) of 1 or less;
  • Prednisone or equivalent glucocorticoid use of less than or equal to 7.5 mg/day; and
  • Tolerating standard immunosuppressant dosing.

The time to achieving LLDAS was compared between treatment groups using Cox regression. The cumulative time to LLDAS was compared using a Cochran–Mantel–Haenszel approach, and responses were compared using logistic regression. All P-values are nominal.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: ACR Convergence, Drug Updates, Meeting Reports Tagged With: ACR Convergence 2021, anifrolumab, SLE, systemic lupus erythematosus (SLE)Issue: June 2022

You Might Also Like:
  • Anifrolumab Promising for SLE
  • Study Says Low Disease-Activity State Can Reduce Lupus Organ Damage
  • Tocilizumab Monotherapy May Sustain Low Disease Activity in RA Patients
  • AstraZeneca Lupus Drug Fails to Meet Main Goal in Study

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)